Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT-123 in advanced solid tumors
NCT04695327Phase 1Completed
- Sponsor
- TILT Biotherapeutics
- Start
- Jan 2021
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad5/3-E2F-D24 in solid tumor, sponsored by TILT Biotherapeutics. Primary endpoints: Adverse Events at 85 days, Abnormal laboratory values at 85 days and 2 more. Started Jan 2021; status: completed.
02
Drugs
Ad5/3-E2F-D24
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04695327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695327.